XXXX dosage requirements: prospective clinical trial of a method for prediction from the response to a single dose.

@entity1 @entity556 @entity1229 @entity22
We have previously described a model for predicting individual daily @entity22 ( @entity22 ) requirements of @entity1229 24 h after the administration of a single dose. This model relies on measurement of the initial anticoagulant response as the 24 h percentage fall in plasma clotting factor VII activity. It permits prediction of the individual @entity22 given the size of the initial dose, a baseline and desired maintenance value of the @entity556 ratio, and a baseline and 24 h plasma level of factor VII activity. We now present the results of a prospective clinical trial of the method. Data from 65 @entity1 were suitable for analysis. The mean daily @entity22 of @entity1229 was 4.0 mg (range 1-10 mg). There was a moderately strong linear relationship between predicted and actual MDs of @entity1229 (r = 0.66, P less than 0.001). Actual vs predicted MDs in individual @entity1 were not significantly different. The mean difference was 0.39 mg. The results of this prospective trial suggest that our model predicts @entity1229 @entity22 requirements with reasonable accuracy. Nevertheless, the accuracy of the model is not sufficient to replace careful clinical and haematological monitoring of each @entity1 commencing @entity1229 therapy.
